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Abstract
Background: The Amazonian medicinal plant Sangre de grado (Croton palanostigma) has traditional
applications for the treatment of wound healing and inflammation. We sought to characterize two extracts
(progrado and zangrado) in terms of safety and oligomeric proanthocyanidin chain length. Additionally
progrado was evaluated for antioxidant activity and possible chondroprotective actions.
Methods: Acute oral safety and toxicity was tested in rats according under OECD protocol number 420.
The profile of proanthocyanidin oligomers was determined by HPLC and progrado's antioxidant activity
quantified by the ORAC, NORAC and HORAC assays. Human cartilage explants, obtained from surgical
specimens, were used to assess chondroproteciton with activity related to direct inhibitory effects on
human matrix metalloproteinase (MMP, gelatinolytic) activity using synovial fluid and chondrocytes
activated with IL-1β (10 ng/ml). Additionally, progrado (2–10 μg/ml) was tested for its ability to maintain
optimal IGF-1 transcription and translation in cartilage explants and cultured chondrocytes.
Results: Both progrado and zangrado at doses up to 2000 mg/kg (po) displayed no evidence of toxicity.
Oligomeric proanthocyanidin content was high for both progrado (158 mg/kg) and zangrado (124 mg/kg),
with zangrado almost entirely composed of short oligomers (<6 mer), whereas the majority of oligomers
in progrado exceeded 10 mers. Progrado was a remarkably potent antioxidant in the standardized tests
ORAC, NORAC and HORAC. Progrado was exceptionally effective in reducing both basal and IL-1β
induced glycosaminoglycan release from human cartilage explants at concentrations that also directly
blocked the gelatinolytic activity of MMP-2 and MMP-9. Progrado prevented IL-1β induced suppression of
IGF-1 production from human cartilage explants as well as stimulating basal IGF-1 production (P < 0.05).
Comparable changes in IGF-1 gene expression were noted in cultured human chondrocytes.
Conclusion:  Progrado has a promising safety profile, significant chondroprotective and antioxidant
actions, directly inhibits MMP activity and promotes the production of the cartilage repair factor, IGF-1.
This suggests that progrado may offer therapeutic benefits in joint health, wound healing and inflammation.
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Background
There is growing interest in natural products as agents to
manage health, particularly from a preventative perspec-
tive. One factor driving this interest is the advancing age
of populations in developed countries and concerns over
the nutrient profile and content of Westernized diets and
its links to disease or poor health [1]. Nevertheless, as die-
tary supplements and natural products are more widely
used, consumers and healthcare providers continue to
require more information on their safety as well as their
efficacy.
For the last decade we have been researching natural prod-
ucts from Amazonian and Andean cultures that are well
appreciated in South America but poorly understood in
other cultures. However, given the diverse and rich flora of
the Amazon River basin and a strong cultural support for
the use of local botanicals, they represent an exciting and
largely untapped opportunity. In the present study we
have focused on the traditional medicine sangre de grado,
which is a dark, red latex tapped from a fast growing tree
[2]. Traditionally sangre de grado is used topically for
wound healing, pruritis, analgesia, and taken orally for
diarrhea, ulcer healing and severe gastrointestinal distress.
Hence it has broad applications within the Amazonian
community. Generally without a clear mechanism of
action these diverse applications are viewed with disbelief
by Western societies. However, in a series of studies we
have confirmed major elements of the traditional knowl-
edge, demonstrating that oral sangre de grado accelerates
the healing of gastric ulcers, prevents neurogenic-medi-
ated intestinal mucosal secretion as a basis for its anti-
diarrheal activity [3], as well as analgesic and antipruretic
properties [4,5]. In terms of wound healing and inflam-
mation sangre de grado extracts limit the transcription of
a wide range of pro-inflammatory cytokines and media-
tors [3] and like green tea catechins promotes the apopto-
sis of various cancer cells [6]. There are other mechanistic
studies on sangre de grado or its extracts that also support
the traditional use, especially for gastrointestinal applica-
tions [7-9].
Throughout these observations we noted that a common
mechanistic thread which was the ability to prevent neu-
rogenic inflammation and specifically the activation of
sensory afferent nerves [4,5]. Capsaicin acting on vanil-
loid receptors is the prototypical agonist for the sensory
afferent nerves leading to the acute symptoms of redness,
swelling, and pain [10]. The ability of sangre de grado to
calm these sensory afferent nerves to a wide range of ago-
nists (prostaglandin E2, protease-activated receptor 2, and
capsaicin) helps explain the anti-itch, anti-nausea and
analgesic properties of the medicinal plant [4,5]. Never-
theless, it is not clear if this neurogenic locus fully explains
the wound healing properties of this traditional medicine
and in this study we investigated other possibilities.
The chemical composition of sangre de grado has been
evaluated [11-13] and one characteristic is its high proan-
thocyanidin content [14]. Proanthocyanidins and other
chemically related polyphenols, catchins and anthocy-
anins, are potent antioxidants, which can modify cellular
responses that are redox regulated [15]. Hence we under-
took to determine the antioxidant potential of a proan-
thocyanidin-enriched extract of sangre de grado
(Progrado®, Rainforest Nutritionals, Inc) using the ORAC,
HORAC and NORAC assays. The oligomeric profile of
progrado and the related extract, Zangrado® was deter-
mined by HPLC. In addition to oral safety and toxicity, we
also explored the concept that progrado may be chondro-
protective.
Previously we have shown that cartilage catabolism can
blocked by other polyphenols – catechins and anthocy-
anins [16-18]. The mechanism underlying this chondro-
protective effect is their ability to suppress redox-sensitive
transcription factors, thereby suppressing genes that pro-
mote catabolism and inflammation. Given that we have
demonstrated that sangre de grado had anti-inflammatory
and wound healing properties, and limited the expression
of pro-inflammatory cytokines and enzymes, we sought to
determine if progrado may affect IL-1β induced cartilage
matrix breakdown and potentially, promote cartilage
repair mechanisms. We have had success in identifying
this pattern of responses in other South American medic-
inal plants that had a traditional use for treating catabo-
lism and inflammation [19].
Methods
Source of medicinal plant extracts and materials
Zangrado® is a proprietary lipidic extract and Progrado ® is
a hydrophilic based extract of sangre de grado (Croton pal-
anostigma), and were obtained from Rainforest Nutrition-
als, Inc (Raleigh, NC), using suppliers in tropical Peru that
incorporate both wild harvesting and cultivation.
Tissue culture medium and related reagents were pur-
chased from either Mediatech (Herndon, VA) or InVitro-
gen (Carlsbad, CA). Recombinant human IL-1β was
purchased from R&D Systems (St Paul, MN), and other
chemicals were purchased from Sigma-Aldrich (Saint
Louis, MO) unless otherwise noted. The extracts were dis-
solved in water and filtered through a 0.45 μm filter under
vacuum prior to use.
Antioxidant assays: ORAC, HORAC, NORAC
These assays were performed by Brunswick Labs (Ware-
ham MA), the independent contract laboratory specializ-
ing in standardized antioxidant assays for food andJournal of Inflammation 2007, 4:16 http://www.journal-inflammation.com/content/4/1/16
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natural products. The ORAC, HORAC and NORAC assays
use the quenching of fluorescent probes as the metric for
antioxidant activity. Results are standardized to a known
antioxidant (trolox or gallic acid) and performed in dupli-
cate or triplicate with results displayed as the means.
Details of the assay procedure can be gleaned from Bruns-
wick Labs website [20].
Proanthocyanidin oligomer composition
Similar to the antioxidant assay tests, this chemical analy-
sis was performed by the contract laboratory, Brunswick
Labs and performed under Good Laboratory Practices.
Total proanthocyanidin content and oligomer profile for
extracts, zangrado and progrado, were determined by
HPLC.
OECD acute oral safety & toxicity
Acute oral toxicity of progrado and zangrado were evalu-
ated separately in sprague dawley rats in compliance with
OECD guidelines for testing of chemicals, Section 4, No.
420 – acute oral toxicity – fixed dose method, adopted
December 17, 2001. This study was conducted in compli-
ance with the principles of Good Laboratory Practice
(GLP) as set forth in OECD Principles of Good Laboratory
Practice (OECD, 1998). All tests were performed by the
contract research organisation, Vedic Lifesciences, Pvt,
Ltd, (Mumbai, India). A sighting study was performed
prior to the main study, in which a female rat was admin-
istered the test article, suspended in water, at a dose of 300
mg/kg body weight. When no mortality or signs of toxicity
were encountered in the sighting study another female rat
was used for an additional sighting study at the dose of
2000 mg/kg. When no mortality or toxicity was noted the
main study was commenced.
On the day of dosing all rats were frequently assessed for
mortality and signs of intoxication following dosing and
thereafter for 14 days. Body weights were recorded at base-
line and weekly thereafter. At the end of the observational
period rats were sacrificed with CO2 asphyxiation and
subjected to a complete necropsy.
Human cartilage explants and cultured chondrocytes
Human OA cartilage samples were procured through the
Tissue Procurement Facility of University Hospitals of
Cleveland/Case Western Reserve University and with
prior approval of the Institutional Review Board of Uni-
versity Hospitals of Cleveland. The cartilage samples were
obtained from patients undergoing total arthroplasty of
the knee due to degenerative joint diseases. In all cases
care was taken to use only "macroscopically normal" car-
tilage samples. No samples were exposed to radiation
solely for the purpose of these studies but almost all the
patients will have received X-rays as part of their clinical
presentation during the execution of care. The same donor
tissue was not used in all experiments but untreated con-
trols were included in all protocols.
Chondrocytes were prepared by the enzymatic digestion
of knee cartilage as previously described [16-19,21].
Chondrocytes were plated (1 × 106 cells/ml) in 35 mm
culture dishes (Becton-Dickinson, Mountain View, CA,
USA) and cultured in DMEM:F12 (Mediatech, Herndon,
VA) supplemented with 10% FCS and 1% Penn:Strep for
72 hrs at 37°C and 5% CO2 in a tissue culture incubator.
Chondrocytes were serum-starved overnight and then
exposed progrado in a water (50 μl/ml, equivalent to 10
μg/ml)) in fresh serum-free medium for 1 hr prior to the
addition of IL-1β (10 ng/ml). Cell viability before plating
was monitored by the MTT assay (Cell Viability and Pro-
liferation Assay) according to the instructions of the man-
ufacturer (R&D Systems). In some cases, chondrocyte
viability after exposure to the different agents was deter-
mined by trypan blue exclusion assay.
Full-thickness cartilage slices (20–25 mg) were dissected
from the cartilage using sterile scalpel blade (Feather
Safety Razor Co., Japan). Four to five cartilage pieces
(approximately equal in size and weight) were transferred
to each well of a 24-well, flat bottom plate (Nunc, Den-
mark) containing DMEM:F-12 (1:1) supplemented with
antibiotics and 10% FCS and cultured for 24 hours. Sub-
sequently the cartilage explants were cultured overnight in
serum free media. The cartilage explants were treated with
IL-1β alone (10 ng/ml) or with IL-1β + progrado for 72 hrs
in serum free media. Explants cultured in the absence of
IL-1β or progrado, were used as controls. Where appropri-
ate, explants were exposed to progrado 15 minutes prior
to the treatment with IL-1β. Total glycosaminoglycan
present in the culture supernatant was estimated as
described below. Two concentrations of progrado were
tested in the cartilage explant studies (2 and 10 μg/ml)
when compared to cultured chondrocytes (2 μg/ml). The
lower dose was used in the cultured chondrocytes because
of a concern that large chain length proanthocyanidin oli-
gomers may not readily diffuse through the cartilage
matrix embedding the chondrocytes in explants, which
was not a constraint for cultured chondrocytes, and
because the more pronounced benefits on IGF-1 produc-
tion were observed at the lower dose.
Release of GAG from cartilage explants
At the end of culture period, the culture medium was col-
lected from each group. A 50 μl aliquot of the collected
supernatant from each sample was utilized to estimate the
total glycosaminoglycan (GAG) concentration by a color-
imetric method employing DMMB as previously
described [22]. Color intensity was read spectrophoto-
metrically at 535 nm using the Lambda 25 spectropho-
tometer (Perkin-Elmer, CT) and the values were derivedJournal of Inflammation 2007, 4:16 http://www.journal-inflammation.com/content/4/1/16
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from a standard curve prepared using different concentra-
tions of glucosamine sulfate. Results are expressed as
micrograms of glycosaminoglycan released per milligram
of cartilage tissue.
IGF-1 production and gene expression
Total cytoplasmic RNA was prepared from primary cul-
tures of human chondrocytes using a commercially avail-
able kit according to the instructions of the manufacturer
(Qiagen, Valencia, CA). Real time quantitative RT-PCR
with internal fluorescent hybridization probes was per-
formed as previously described [17,19] and the IGF-1
gene expression was quantified using a commercially
available Gene Expression Assay kit (Applied Biosystems,
CA). Expression of IGF-1 mRNA was normalized to β-
actin mRNA expression, and the results were expressed as
fold induction relative to controls. Human IGF-1 level in
cartilage explant media was quantified using a commer-
cially available Human IGF-1 ELISA kit (R & D Systems)
per manufacturer's directions.
Inhibition of gelatinolytic enzyme activity
As gelatinases, reflecting the activity of matrix metallopro-
teinases, have been implicated in cartilage matrix break-
down and joint degradation in osteoarthritis, we
determined the extent to which progrado directly inhibits
gelatinase activity using gelatin zymography. Synovial
fluid from osteoarthritis patients and culture supernatant
of IL-1β-stimulated human chondrocytes was used as
sources of matrix metalloproteinase activity. Human
chondrocytes were prepared by the enzymatic digestion of
non-affected osteoarthritis cartilage and plated at 1 × 106/
ml in complete medium as described above. When cul-
tures were 80% confluent they were stimulated with IL-1β
for 24 hrs in serum free medium. Culture media after this
treatment was used for gelatinolytic activity. The synovial
fluid and culture media were divided into 4 aliquots and
resolved on gelatin containing 8.5% acrylamide gels as
described [23]. The lanes were cut and incubated over-
night in TCNB buffer (50 mM Tris.HCl pH 7.4, 5 mM
Ca2+, 0.1 mM Zn2+, 150 mM NaCl, 0.035% Brij-35) con-
taining either no progrado or at 1,2 and 4 μg/ml progrado.
The gel was then fixed and stained with Coomassie Bril-
liant Blue R-350 (GE Healthcare) using standard proto-
cols. Gelatinase activity was evident as cleared regions on
a blue background. Similar results (not shown) were
obtained when recombinant human MMP-9 was used.
Composite images were analyzed using the Alpha-
Innotech image analysis software. Band intensities (in pix-
els) of MMP-9 (95 kDa) or MMP-2 (72 kDa) in each lane
were totaled with values in control (no Progrado) repre-
senting 100%. Percent inhibition from untreated controls
was calculated using Sigma Plot software.
Statistics and data analysis
Data was analyzed using the software package, Instat®,
and the analysis included one way ANOVA followed by an
appropriate post hoc test (Tukeys or Dunnett's). Values
are expressed as mean ± SEM. Differences were considered
significant at P < 0.05.
Results
Proanthocyanidin content and form
Analysis of proanthocyanidin content and oligomer
length for zangrado and progrado was performed by
Brunswick Labs (Wareham, MA) by HPLC. The proan-
thocyanidin content was substantial in both zangrado
(124 mg/g) and progrado (158.1 mg/g). Zangrado was
composed of primarily short length oligomers (less than
6 mer), whereas longer length oligomers, particularly
those above 10 mer in length, were present in abundance
in progrado (Figure 1). This proanthocyanidin chain
length difference between the two extracts may contribute
to the difference in the color of these two extracts. Absorb-
ance measured at 414 nm, where progrado was nearly 5
times greater than zangrado (data not shown), reflecting
its more intense red/brown color.
Acute oral safety and toxicity: OECD guide
Oral safety and toxicity studies for zangrado and progrado
was performed by Vedic Lifesciences, Pvt. Ltd. Vedic is a
contract research organization with a natural products
focus. The analyses were performed in rats according to
the standard protocols outlined by the OECD (Section 4,
Number 420, adopted 12/2001) in accordance with the
principles of Good Laboratory Practice (OECD, 1998).
Both investigational agents were tested in a sighting study
at 300 mg/kg, followed by another sighting study at 2000
mg/kg (for both sighting studies n = 1) and then a follow-
up main study at 2000 mg/kg (n = 4).
Treatment with both investigational agents at these high
doses did not cause weight loss, the expected result if there
was systemic toxicity. Indeed, normal weight gain was
observed for both progrado and zangrado (Fig. 2) follow-
ing treatment at 2000 mg/kg. At the highest dose tested
2000 mg/kg, no toxicity was noted at necropsy indicated
by a total lack of gross pathological alterations or clinical
signs of abnormalities during the 14 day observation
period. As a result both progrado and zangrado according
to the Global Harmonised System (GSH) for classification
of chemicals which cause acute toxicity, OECD series on
testing and assessment, Number 33: has to be classified in
GSH Category 5/Unclassifiable for the obligatory labeling
requirement for oral toxicity. This is the highest possible
safety rating in this test.Journal of Inflammation 2007, 4:16 http://www.journal-inflammation.com/content/4/1/16
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Antioxidant assays; ORAC, NORAC and HORAC
These assays are a series of tests that evaluate the ability of
agents to quench specific free radicals and oxidants. The
ORAC assay is designed to measure the quenching of per-
oxyl radicals and uses trolox, a water-soluble vitamin E
equivalent, as a reference standard. HORAC differs in that
it measures the ability to quench the hydroxyl radical,
with values expressed as mg gallic acid equivalents/gram.
Finally the NORAC is an assay that is specific for peroxyni-
trite (a powerful oxidant and nitrating agent) and results
are quantified in μmole of trolox equivalents/gram.
Only progrado was tested and results are summarized in
Table 1. It is clear that progrado possesses a remarkable
antioxidant activity across a broad range of assays. While
the antioxidant activity was quantified to reference anti-
oxidants (trolox or gallic acid) comparisons to common
foods, nutraceuticals and natural products and figures can
be accessed from Brunswick Labs website [20]. Briefly to
aid perspective, progrado has an ORAC capacity that is
450× most nuts, 75× fresh blueberries and equivalent to
powdered blueberry extracts. For the NORAC assay pro-
grado is 21× a red wine extract and 2.3× more effective
than grape seed extracts.
Chondroprotection in human cartilage explants
Progrado was analyzed for its ability to modify basal and
IL-1β stimulated GAG release from human cartilage
explants. Progrado was able to profoundly lower basal
GAG release (10 μg/ml, P < 0.01), a result that may sug-
gest that direct inhibition of matrix metalloproteinases
(Fig. 3). The addition of the pro-inflammatory, catabolic
cytokine IL-1β to the explant media was able to stimulate
the release of GAGs into the media (P < 0.01). This effect
is thought to reflect an up-regulation of MMP production
secondary to an enhanced gene expression [16-18,21].
Progrado effectively blocked IL-1β stimulated release of
GAG from the cartilage explants in a dose-dependent
manner (P < 0.01), and indeed reduced media GAG levels
to well below baseline despite the presence of IL-1β.
IGF-1 by Human Cartilage and Progrado
Cartilage growth and repair is largely controlled by local
growth factors, the most important of which is IGF-1.
During states of inflammation cartilage matrix is degraded
as mimicked in Figure 4, where IL-1β stimulated GAG
release in human cartilage explants (P < 0.05). During
inflammation when cartilage is in a catabolic state, repair
mechanisms are suppressed or rendered dormant. This is
reproduced in Figure 4, where administration of IL-1β to
human cartilage explants at a dose that promotes cartilage
catabolism results in a suppression of IGF-1 production
(P < 0.05). However, when progrado is co-administered
with IL-1β, this suppressed production of IGF-1 is pre-
vented, with normal IGF-1 production maintained at 10
μg/ml and an increase above basal values observed with
the combination of IL-1β and low dose progrado (2 μg/
ml, Fig. 5, P < 0.01). When high dose progrado (10 μg/ml)
was incubated with unstimulated cartilage explants there
is a reduction in IGF-1 production below control values
(Fig. 5, P < 0.01). This indicates that while progrado may
promote anabolic mechanisms responsible for repair of
damaged, inflamed cartilage it appears that these actions
are less pronounced at 10 than 2 μg/ml.
IGF-1 gene expression in chondrocytes
Following the ability of progrado to promote the forma-
tion of IGF-1 production from human cartilage explants
we elected to extend this observation by examining the
ability of progrado to promote IGF-1 gene expression in
primary cultures of human chondrocytes. Based on the
observations in Figure 4, where low doses were more
effective we only evaluated the low dose of progrado (2
μg/ml) in this assay. As shown in Figure 5, progrado (2 μg/
ml) was able to promote the expression of IGF-1 in
human chondrocytes under basal conditions (P < 0.001),
confirming the data obtained with IGF-1 protein levels in
cartilage explants. Consistent with the reduction of IGF-1
protein levels by IL-1β in explants, IL-1β significantly low-
ers IGF-1 gene expression in cultured chondrocytes (P <
0.001). Further, progrado (2 μg/ml) was effective in
blocking the suppressive effects of IL-1β, and indeed
raised IGF-1 mRNA levels above control levels despite the
Proanthocyanidin oligomer length for zangrado and progrado Figure 1
Proanthocyanidin oligomer length for zangrado and 
progrado. Oligomer length as determined by HPLC was dis-
tinctive for the two extracts, zangrado and progrado, of san-
gre de grado (Croton palanostigma). Short length oligomers 
were the main source of proanthocyanidins in zangrado, 
whereas progrado consisted of long chain oligomers. Results 
reflect mean values for each oligomer length for triplicate 
analysis.
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presence of IL-1β (P < 0.001). This observation also
matched what was observed in terms of IGF-1 production
in cartilage explants (Fig. 4). This pattern of observations
indicates that restorative pathways in human cartilage that
are reduced with chronic inflammation may be main-
tained with progrado treatment.
Inhibition of MMP activity
Activity of MMP-9 was completely suppressed at progrado
concentrations of 4 μg/ml, while MMP-2 activity was
inhibited 90%, whether the source was synovial fluid (Fig-
ure 6) or media of activated chondrocytes (Figure 7). In
contrast to the small differences in maximal inhibition by
progrado on MMP-2 and MMP-9 activity, within the dose
range examined in this protocol, MMP-2 activity appeared
to be more sensitive to inhibition by progrado at concen-
trations below 4 μg/ml. These results clearly show that
progrado is an effective inhibitor of the gelatinase activity
present in osteoarthritis, and that this actions is demon-
strated at the same concentrations of progrado that are
chondroprotective and augments the chondrocyte expres-
sion and production of IGF-1.
Discussion
In the acute oral toxicity tests both the zangrado and pro-
grado extracts were given a GSH rating of 5 or unclassifia-
ble. This is the top rating in this test and suggests that
these extracts are particularly safe under these conditions.
The parent medicinal plant sangre de grado, is tradition-
ally used at low doses in Amazonia, as confirmed in our
previous in vivo studies [3,4], and this is suggestive of a
therapeutic window that is indeed large. Nevertheless,
additional safety studies, especially chronic studies will be
necessary to properly frame the applicability of these
extracts as therapeutic agents.
The high proanthocyanidin content in both extracts is in
keeping with the robust antioxidant activity. The majority
of this report was focused on the profile of progrado, as
zangrado has been evaluated in a number of in vitro, in
vivo and clinical trial settings [3-5]. Progrado's antioxi-
dant profile is indeed significant. The NORAC activity of
progrado, which is an index of peroxynitrite quenching,
was particularly exceptional. Peroxynitrite is formed from
the free radicals superoxide and nitric oxide, and is
thought to contribute to a wide range of pathological
states [24], based on its nitrating and oxidant activities.
Interestingly in healing gastric ulcers we confirmed that
sangre de grado therapy reduces the expression of induci-
ble nitric oxide synthase (iNOS) in the ulcer bed, along
with IL-1β, IL-6, TNFα and COX2, so it may limit the tis-
sue burden of peroxynitrite by molecular quenching
(NORAC test) and by limiting the production of nitric
oxide, peroxynitrite's molecular parent, by suppressing
iNOS gene expression [3].
Suppressing redox related transcriptional events is a hall-
mark of polyphenols [14,25,26], a characteristic that we
refer to as genonutrients, or nutrients that can affect gene
expression. This has lead many to investigate the utility of
these and related antioxidants as therapeutic agents in tis-
sue injury and inflammation. In this study we focused on
transcription related events in human cartilage to serve as
a window as to the potential therapeutic applicability of
progrado in osteoarthritis and related joint disorders. IL-
1β is a major determinant of catabolic events in cartilage,
which results from the stimulation of matrix metallopro-
Weight gain following a single oral dose: Acute oral toxicity Figure 2
Weight gain following a single oral dose: Acute oral 
toxicity. Body weights of rats treated with either progrado 
(n = 5) or zangrado (n = 5) at 2000 mg/kg administered orally 
in accordance with OECD test 420. Weight was measured at 
baseline and day 7 and 14 and depicted as the mean ± sem. 
The * represents a significant difference from baseline (P < 
0.05) and the ** indicates a significance level of P < 0.01.
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Table 1: Antioxidant profile of progrado.
Agent ORAC μmole TE/g HORAC mg GAE/g NORAC μmole TE/g
Progrado 4,552 269 937
ORAC (peroxyl radical quenching) is measured in trolox equivalents/g, HORAC (hydroxyl radical quenching) in gallic acid equivalents/g, and 
NORAC (peroxynitrite quenching) in trolox equivalents/g. Results are expressed as means of duplicate studies.Journal of Inflammation 2007, 4:16 http://www.journal-inflammation.com/content/4/1/16
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teinases (MMPs) transcription and translation, which in
turn digest the cartilage matrix. Experimentally this is then
quantified in vitro by the release of GAG from cartilage
explants [22].
We have previously demonstrated that the catechin, epi-
gallocatechin gallate (EGCG) can negate cartilage IL-1β
mediated cartilage breakdown by limiting MMP gene
expression via a suppression of redox-regulated transcrip-
tion factors like NF-κB [16,17]. This benefit was also evi-
dent in an animal model of rheumatoid arthritis [21],
indicating the potential in vivo and therapeutic applica-
bility of these events. Similarly, anthocyanin-rich pome-
granate fruit extracts prevented cartilage matrix loss
through transcription events [17].
Given that we have shown that catechins and anthocyani-
dins can protect cartilage [16-18,21] and are polyphenols
that are chemically related to proanthocyanidins, we
decided to evaluate the potential utility of progrado in this
model of inflammation mediated joint damage. This
application is slightly distinct from the traditional use
which focuses on promoting skin wound healing and
treating itch, pain and gastrointestinal disorders, but
given the background information on composition and
mechanisms of action it was deemed worthy of investiga-
tion. The present results exceeded expectations and indi-
cate that progrado possesses within the same
concentration range, a collage of activities that are poten-
tially important for joint health and restoration.
Progrado was clearly chondroprotective as evidenced by
the blocking of IL-1β induced cartilage catabolism (GAG
release). Indeed GAG release was lowered below baseline
values even in the presence of IL-1β. In general it is
thought that IL-1β mediated matrix breakdown is due to
increased MMP expression and activation in an arthritic
joint, whereas basal GAG release is thought to reflect the
actions of MMPs that are already present and active. Based
on the ability of progrado to lower cartilage explant GAG
release below baseline values, we extended the analysis to
assess whether progrado directly affected MMP activity
using gelatin zymography. Using the contrasting but
related sources of synovial fluid from osteoarthritis sub-
jects and the media from IL-1β activated human chondro-
cytes, we noted a dramatic suppression of MMP activity
with progrado over the same concentration range that
demonstrated chondroprotection and raised production
of the anabolic repair factor, IGF-1. Individually these are
important outcomes for joint health, but as a compen-
Cartilage explant production of IGF-1 and the effects of IL-1β  and progrado Figure 4
Cartilage explant production of IGF-1 and the effects 
of IL-1β and progrado. Control, untreated human carti-
lage explants release a defined amount of IGF-1 into the 
bathing media. Cartilage release of IGF-1 was significantly 
reduced by IL-1β (10 ng/ml, * P < 0.05). Co-treatment with 
progrado 2 or 10 μg/ml restored and raised IGF-1 produc-
tion above basal controls (** P < 0.01). This effect was more 
pronounced with the lower dose of progrado (2 μg/ml) than 
the higher dose (10 μg/ml). In the absence of IL-1β, progrado 
(10 μg/ml) reduced IGF-1 production basal values (* P < 
0.01). Results are depicted as the mean ± sem.
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Cartilage matrix breakdown as measured by the release of  glycosaminoglycan Figure 3
Cartilage matrix breakdown as measured by the 
release of glycosaminoglycan. Treatment of human carti-
lage explants with IL-1β (10 ng/ml) results in the release of 
glycosaminoglycans (GAG) into the media (* P < 0.01). Co-
administration of progrado (2 or 10 μg/ml) blocked the IL-1β 
induced GAG release and resulted in a significant reduction 
in media levels of GAG (** P < 0.01) below the IL-1β and 
untreated control response. Explants treated with progrado 
alone (10 μg/ml) also produced a dramatic reduction in 
media GAG levels to that evident with progrado + IL-1β (** 
P < 0.01). Results are depicted as the mean ± sem.
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dium of actions it is a novel and potentially important
observation.
Recently we described the ability of extracts of two South
American medicinal plants (Vincaria® and RNI 249) from
cat's claw (Uncaria guianensis) and maca (Lepidium meye-
nii) respectively, to exert chondroprotective actions in this
human cartilage explant model [19]. These agents negated
IL-1β induced GAG release as seen with EGCG and pome-
granate fruit extracts but unlike progrado, they did not
lower basal GAG release to the extent seen here with pro-
grado. The combination of South American medicinal
plant extracts vincaria and RNI 249, also raised the expres-
sion of the anabolic growth factor, IGF-1 in human
chondrocytes, with their combined effects being additive
[19]. This combination of medicinal plant extracts was
recently evaluated in a positive controlled randomized
clinical study in subjects with osteoarthritis, with signifi-
cant benefits based on response rates and effect size
(unpublished results) and has been commercialized
under the name Reparagen®. The importance of this
approach centers on the role that IGF-1 plays in repairing
and regenerating cartilage [26-29]. Similarly, this present
study progrado was able to maintain normal IGF-1 pro-
tein and mRNA levels despite the presence of IL-1β in
human chondrocytes, indicating that progrado may
potentially be disease modifying by limiting joint destruc-
tion and promoting repair.
While the present study did not measure frank repair or
cartilage growth, IGF-1 is a well-known mediator of carti-
lage anabolism or repair [26-29]. Hui et al. [28] demon-
strated that IGF-1 blocks the production of a range of
MMPs in response to IL-1β which may contribute to the
chondroprotective actions of progrado. However, in addi-
tion to secondary actions on catabolism via IGF-1, pro-
grado directly inhibits MMP activity at the same
concentrations that it promotes IGF-1 production by
chondrocytes. Madry et al., [30] described cartilage repair
by using transplanted chondrocytes that over-expressed
IGF-1, which represents another exciting approach to the
issue of joint repair. The suppression of repair processes
like IGF-1 during inflammation may explain why glu-
cosamine supplementation, which is a substrate used by
growth factors for cartilage regeneration, has variable ben-
efits [31,32]. It is intriguing to consider that approaches
that restore these joint repair processes while limiting
joint destruction may not only be a more effective alterna-
tive, but may render substrate-based approaches glu-
cosamine and chondroitin more reliable.
Conclusion
Extracts of Croton palanostigma, a traditional Amazonian
medicinal plant, were found to have an excellent acute,
oral safety profile and high concentrations of oligomeric
proanthocyanidins. Progrado an extract enriched for long
chain proanthocyanidin oligomers possessed a significant
antioxidant activity and in human cartilage prevented cat-
abolic breakdown of the cartilage matrix. The chondro-
protective actions are associated with a direct inhibition of
MMP activity and enhanced chondroycte expression and
production of IGF-1, an anabolic growth factor known for
cartilage repair. Natural products approaches like pro-
grado, with diverse and interrelated actions on inflamma-
tion and repair mechanisms may offer an important
option for managing joint health. Nevertheless further
evaluation in more complex environments is needed to
determine if these proanthocyanidin enriched extracts
provide meaningful therapeutic value in arthritis, joint
injury and repair.
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IGF-1 mRNA levels in cultured human chondrocytes and the  effects of IL-1β and progrado Figure 5
IGF-1 mRNA levels in cultured human chondrocytes 
and the effects of IL-1β and progrado. Primary cultures 
of human chondrocytes taken from surgical explants were 
examined for IGF-1 gene expression using real time RT-PCR. 
Basal expression was normalized to the house keeping gene 
β-actin. Given that lower doses of progrado were more 
effective in raising IGF-1 production and cultured chondro-
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treatment with progrado (2 μg/ml) and IL-1β resulted in a 
significant increase in IGF-1 gene expression above untreated 
controls and IL-1β treatment (** P < 0.001). Treatment with 
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levels above all other groups (** P < 0.001). Results 
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MMP matrix metalloproteinase
NF-κB nuclear factor kappa B
IL-1β interleukin 1 beta
IL-6 interleukin 6
TNFα tumor necrosis factor alpha
COX2 cyclo-oxygenase 2
GAG glycosaminoglycan
OECD organization for economic co-operation and
development
ORAC oxygen radical absorbance capacity
HORAC hydroxyl radical absorbance capacity
NORAC peroxynitrite radical absorbance capacity
INOS inducible nitric oxide synthase
EGCG epigallocatchin gallate
RT-PCR reverse transcriptase polymerase chain reaction
GSH global harmonized system
HPLC high performance liquid chromatography
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MMP activity from culture media of IL-1β treated human  chondrocytes and the inhibitory effects of progrado Figure 7
MMP activity from culture media of IL-1β treated 
human chondrocytes and the inhibitory effects of 
progrado. Subconfluent human chondrocytes were treated 
with IL-1β (10 ng/ml) to stimulate the release of matrix met-
alloproteinases, measured as MMP and MMP-9 using gelatin 
zymography. Progrado was associated with a dose-depend-
ent inhibition of both MMP-2 and MMP-9 activity. Complete 
inhibition of MMP-9 was evident at 4 μg/ml, with MMP-2 
activity reduced by approximately 90%.
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MMP Activity from synovial fluid of subjects with osteoarthri- tis and the inhibitory effects of progrado Figure 6
MMP Activity from synovial fluid of subjects with 
osteoarthritis and the inhibitory effects of progrado. 
Synovial fluid from subjects with active osteoarthritis was 
used as a source of matrix metalloproteinase gelatinolytic 
activity using gelatin zymography. Recombinant MMP-2 and 
MMP-9 was used for identification of gelatinolytic activity. 
Progrado was associated with a dose-dependent inhibition of 
both MMP-2 and MMP-9 activity. Complete inhibition of 
MMP-9 was evident at 4 μg/ml, with MMP-2 activity reduced 
by approximately 90%.
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